Sepsis is a leading cause of death which is characterized with uncontrolled inflammatory response. In this study, we report that scavenger receptor BI (SR-BI), an HDL receptor, is a critical survival factor of sepsis. We induced sepsis using an established septic animal model, cecal ligation and puncture (CLP). CLP induced 100% fatality in SR-BI null mice, but only 21% fatality in wild type littermates. SR-BI null mice exhibited aberrant inflammatory responses with delayed inflammatory cytokine generation at the early stage of sepsis and highly elevated inflammatory cytokine production 20 hours after CLP treatment. To understand the mechanisms underlying SR-BI protection, we elucidated the effect of macrophage SR-BI on inflammatory cytokine generation. Macrophages from SR-BI null mice produced significantly higher levels of inflammatory cytokines than those of wild type controls in response to LPS. Importantly, transgenic mice overexpressing SR-BI were more resistant to CLP-induced septic death. Using an HEK-Blue cell system, we demonstrated that expression of SR-BI suppressed TLR4-mediated NF-κB activation. To understand why SR-BI null mice had a delayed inflammatory response, we elucidated the effect of SR-BI on LPS clearance during sepsis. Compared to wild type controls, SR-BI null mice had lower plasma LPS levels in the early stage of sepsis and elevated plasma LPS levels 20 hours following CLP treatment.
protective function (26) . These studies suggest that SR-BI might play a role in sepsis. Interestingly, using in vitro cell culture, Vishnyakova et al. recently reported that SR-BI enhances the uptake of Gram-negative bacteria, which raises a possibility that this SR-BI-mediated bacterial uptake may facilitate bacterial infection and therefore play a deleterious role in sepsis (27) . Given the limitations of endotoxemia animal model (28) , it is of importance to determine whether and how SR-BI plays a protective role in sepsis. In this study, we assessed the role of SR-BI in sepsis using an established septic animal model, cecal ligation and puncture (CLP). We demonstrated that SR-BI is a critical survival factor of sepsis in mice. In contrast to significant protection against LPS-induced animal death by SR-BI-mediated corticosterone generation, corticosterone did not provide protection against CLP-induced septic animal death, indicating that SR-BI has other functions than regulating corticosterone production in sepsis. Using a transgenic animal model, primary macrophages and HEK-blue cell system, we demonstrated that SR-BI modulates inflammatory response in macrophages via TLR4 signaling, which contributes to protection against septic death.
Experiential Procedures
Materials: Anti-SR-BI serum was custom made by Sigma-Genosys using a 15 amino acidpeptide derived from the C-terminal of human SR-BI. LPS (E. coli serotype K12) was from InvivoGen. Endo-low FBS was from Hyclone. M-CSF was from R&D Systems. Corticosterone was from Sigma. Blood agar plate (MacConkey II) was from BD Bioscience. ELISA kits for quantifying TNF-α and IL-6 were from eBioscience. Competitive ELISA kit for quantifying mouse cortisol or corticosterone, and nitrite/nitrate (NOx) kit were from Cayman. ELISA kit for quantifying LPS was from Charles River.
SR-BI null mice:
SR-BI +/-mice on C57BL/6x129 background were obtained from the Jackson Laboratories. SR-BI -/-, SR-BI +/-and SR-BI +/+ littermates were generated by breeding SR-BI +/-mice. Mouse tail DNA was used for PCR genotyping. The animals were fed with standard laboratory chow diet. Animal care and experiments were approved by the Institutional Animal Care and Use Committee of the University of Kentucky.
Generation of SR-BIC323G transgenic mice: C323G mutated SR-BI cDNA was generated and subcloned into pCAGGS vector as previously described (21) . The transgenic mice in C57BL/6xCBA background were generated by Transgenic Core Facility of Mayo Clinic (Scottsdale, Arizona). Transgenic mice were selected by PCR using tail DNA. The transgenic mice were crossed to SR-BI null mice to generate transgenic and non-transgenic littermates in SR-BI null background. The breeders were fed with 0.1% Probucol to correct female infertility.
CLP septic animal model: CLP was performed as described by Wesche-Soldato et al (29) . Briefly, 10-to 12-week-old mice were anesthetized by inhalation of 2-5% isoflurane in 100% oxygen using anesthesia equipment. A midline incision (1.0 cm) was made below the diaphragm. The cecum was isolated, ligated, punctured twice with a 22-gauge needle, and gently compressed to extrude a small amount of cecal material. The cecum was returned to the abdomen, and the muscle and skin incisions were closed with 6-0 Ethilon suture material. The mice were subsequently resuscitated with 1 ml PBS subcutaneously. Sham animals were similarly treated without ligation/puncture of the cecum. The survival was monitored for a 5-day period.
Biochemical assays: 10-to 12-week-old mice were euthanized by CO 2 inhalation 2, 4, 8 and 20 hours following CLP. The blood was obtained by cardiac puncture or tail bleed and stored at -80 o C. The serum ALT levels were quantified with Analyst Chemistry System, which were used to determine the degree of liver damage; the serum nitrite/nitrate (NOx) levels were measured with a nitrite/nitrate kit, which were used to estimate the generation of NO in vivo; the serum TNF-α, IL-6, corticosterone or LPS levels were quantified with corresponding ELISA kits. Supplementation of corticosterone: Corticosterone was administered to 10-to 12-week-old SR-BI null mice following the method described by Cai et al. (26) . Then the CLP was performed and the survival was monitored for a 5-day period.
Quantification of cytokine generation in LPSstimulated macrophages: Bone marrow derived macrophages were cultured as described previously (30) . Briefly, bone marrow cells were cultured in 6-well plate at 2 x 10 6 cells/well in RPMI1640 medium containing 20% FBS and 25 ng/ml of mouse M-CSF for 6 days. The medium was changed daily. For measurement of cytokines, the cells were incubated in PBS for 2 hours and treated with LPS at 0, 0.25, 0.5 and 1 ng/ml for 2, 4, 8 and 20 hours in RPMI1640 medium containing 20% FBS, and cytokines in the culture supernatant were quantified with corresponding ELISA kit.
Generation of HEK-Blue cells stably expressing wild type and C323G mutant SR-BI:
HEK-Blue cells, which stably express TLR4, CD14, MD2 and a NF-κB reporter, were from InvivoGen. The HEK-Blue cells were transfected with wild type SR-BI, C323G mutant SR-BI cDNA or pLNCX2 vector and mixed clones stably expressing SR-BI, SR-BIC323G or vector were obtained by G418 selection.
Analysis of TLR4-mediated NF-κB activation: HEK-Blue cells stably expressing SR-BI, SR-BIC323G or pLNCX2 vector were cultured in 96-well plate in complete DMEM medium containing 0.5 mg/ml G418 and 10% Endo-low FBS to 90% confluency and treated with LPS at 0, 0.5, 1 and 2 ng/ml for 16 hours. Then, 100μl of the culture supernatant was mixed with 100μl HEK-Blue™ Detection Medium and incubated at 37 o C for 1 hour. LPS activates TLR4 resulting in induction of NF-κB reporter expression, which catalyzes the HEK-Blue™ Detection medium to blue. The blue color was quantified by measuring absorption at 650nm.
Lipoprotein profiling by FPLC: Serum (50 µl) was resolved by gel filtration chromatography with FPLC equipped with a Superose 6 column (Pharmacia LKB Biotechnology Inc.). The column was eluted at a flow rate of 0.5 ml/min in buffer containing 150 mM NaCl, 10 mM Tris/HCl pH 7.4, 0.01% sodium azide, and 0.5 ml/fraction was collected. One hundred microliters of sample was mixed with 100µl of 2x assay reagent to determine the cholesterol content of fractions (Wako Chemicals).
Analysis of bacteremia: Blood was diluted to 100 and 1000 times with PBS, and 200 μl of the diluted blood was plated on MacConkey II agar plate. After 24 hours incubation at 37 C, the number of purple clone was counted. qPCR analysis was employed to quantify the number of bacteria in the liver following the method described by Steinman et al. (31) . Total DNA was isolated from 30mg of liver using DNeasy kit (QIAGEN). The qPCR was performed with bacteria specific primers (Forward, 5'-GAGGAAGGIGIGGAIGACGT; reverse, 5'-AGGAGGTGATCCAACCGCA) using knowing number of DH-5α bacteria as standard.
Statistical Analysis: The survival assay was analyzed by Log-Rank x 2 test using SAS software. Significance in experiments comparing two groups was determined by 2-tailed Student t-test. Significance in experiments comparing more than two groups was evaluated by One Way ANOVA, followed by post hoc analysis using Tukey's test. Means were considered different at p < 0.05.
RESULTS

SR-BI is a critical survival factor in CLPinduced septic death.
We employed a wellestablished CLP sepsis model to determine whether SR-BI is required for protection against bacteria-induced septic death. As shown in Figure  1a , mice deficient in were significantly more susceptible to CLP-induced septic death. CLP treatment induced 19% fatality in SR-BI null mice and 5% in wild type littermates at 24 hours; 90% fatality in SR-BI null mice and 10% in wild type littermates at 48 hours, and 100% fatality in SR-BI null mice but only 21% fatality in wild type littermates at 72 hours. SR-BI-mediated protection against CLP-induced liver injury was assessed by measuring serum alanine aminotransferase (ALT) levels. Compared to wild type controls, SR-BI null mice had a significant increase in serum ALT levels ( Figure 1b ) 20 hours following CLP treatment. These findings indicate that SR-BI is a critical survival factor in sepsis.
Aberrant innate immune response in SR-BI null mice during sepsis. Rapid innate immune response that generates high levels of inflammatory cytokines constitutes the first line of the self defense system against bacterial infections. However, uncontrolled production of cytokines is a major cause of septic death (32) . To understand why SR-BI null mice are susceptible to septic death, we assessed inflammatory cytokine production in CLP-treated SR-BI null and wild type littermates. We treated the mice with CLP for 2, 4, 8 and 20 hours and then determined the serum cytokine levels. As shown in Figure 2 , SR-BI null and wild type mice exhibited distinct inflammatory responses during sepsis. Wild type mice exhibited a typical acute phase response with a rapid and strong induction of TNF-α and IL-6 in the early stage of sepsis (2 to 8 hours) and significantly decreases in TNF-α and IL-6 levels by 20 hours. However, SR-BI null mice exhibited an aberrant pattern of inflammatory cytokine generation during sepsis. Four hours after CLP treatment, although serum TNF-α and IL-6 levels increased in SR-BI null mice, the increases were significantly less than that of wild type control mice, indicating a delayed immune response in SR-BI null mice. Interestingly, in contrast to the decrease in cytokine levels in wild type mice 20 hours after CLP treatment, the serum TNF-α and IL-6 levels continued to increase in SR-BI null mice, indicating a prolonged and uncontrolled cytokine generation in the late stage of sepsis in the absence of SR-BI ( Figure 2 , a and b).
Like cytokines, NO is another key molecule in innate immune response during sepsis (33) . Upon bacterial infections, iNOS expression in macrophages is induced to generate high level of NO, which is used to kill bacteria and modulate immune reactions (33) . However, too much NO is deleterious and can cause oxidative cell damage (34) . We measured serum nitrite and nitrate (NOx) levels to determine whether SR-BI affects NO production in sepsis. As shown in Figure 2c , SR-BI null mice exhibited an aberrant pattern of NO generation during sepsis. In contrast to an increase in NO generation in the early stage of sepsis in wild type mice, the NO generation in SR-BI null mice was significantly less than that of wild type controls, indicating a delayed NO generation in SR-BI null mice. Furthermore, unlike the gradual decrease in NOx levels in the late stage of sepsis in wild type mice, the serum NOx levels in SR-BI null mice reached the peak at 8 hours and remained high at 20 hours, indicating a prolonged NO generation in the late stage of sepsis in the absence of SR-BI.
Contribution of SR-BI-mediated corticosterone generation to sepsis. SR-BI is highly expressed in adrenal glands. It mediates the intracellular uptake of cholesterol from HDL in adrenal glands, thus providing substrate for corticosteroid synthesis (35) . A recent study by Cai et al. showed that SR-BI null mice have a defect in inducible corticosterone generation in LPS-challenged mice and supplementation of corticosterone to LPS-challenged SR-BI null mice rescues the mice from endotoxic death, indicating that SR-BI-mediated corticosterone production contributes to its protection against endotoxic animal death(26). We elucidated the effect of SR-BI on corticosteroid generation during sepsis by measuring serum corticosterone levels. As expected, CLP induced a 4-fold increase in corticosterone generation in wild type mice 4 hours following CLP treatment (SR-BI +/+ basal, 198 ± 55 ng/ml vs. SR-BI +/+ CLP, 830 ± 189 ng/ml), but mice deficient in SR-BI failed to generate any inducible corticosterone during sepsis (SR-BI -/-basal, 165 ± 33 ng/ml vs. SR-BI -/-CLP, 160 ± 67 ng/ml) (Figure 3a ), indicating that SR-BI is required for inducible corticosterone production during sepsis. To determine whether this SR-BI-mediated corticosterone production contributes to its protection against septic death, we administered corticosterone in drinking water to SR-BI null mice 8 hour prior CLP treatment following the method described by Cai et al. (26) . Unexpectedly, in contrast to significant protection against LPS-induced endotoxic animal death by corticosterone (26) , corticosterone supplementation failed to protect SR-BI null mice from CLP-induced septic death (Figure 3b ). The data clearly indicate that SR-BI is required for inducible corticosterone production during sepsis, but this SR-BI-mediated inducible corticosterone production is not responsible for protection against septic death.
SR-BI modulates inflammatory cytokine generation in macrophages. We then looked for an alternative explanation for SR-BI protection against septic death. Considering that SR-BI is expressed in macrophages and that macrophages are one of the major types of cells that generate inflammatory cytokines during sepsis (36,37), we determined whether SR-BI directly affects cytokine production using bone marrow-derived macrophages. We treated the macrophages with 0.5 ng/ml of LPS and quantified TNF-α and IL-6 production. Wild type and SR-BI null macrophages exhibited distinct inflammatory responses to LPS stimuli ( Figure 4, b and c) . For wild type macrophages, TNF-α production reached its maximum level by 4 hours and IL-6 production reached maximum level by 8 hours.
However, for SR-BI null macrophages, the TNF-α and IL-6 levels continued to rise and surpassed cytokine levels of wild type macrophages by 20 hours, indicating uncontrolled TNF-α, and IL-6 generation in macrophages deficient in SR-BI. We also treated the macrophages with various amounts of LPS. In the presence of pathological levels of LPS, LPS induced the generation of TNF-α and IL-6 in a LPS dose-dependent manner and the presence of SR-BI effectively suppressed the generation of TNF-α and IL-6 ( Figure 4, d and  e) .
Macrophage SR-BI provides protection against septic death. We used SR-BI transgenic mice to determine whether expression of SR-BI in macrophages contributes to protection against septic death. In using this approach, an important consideration is our ability to distinguish the effect of SR-BI on modulating inflammatory response in macrophages from its effects on inducing apoptosis, protecting NO-induced cytotoxicity and regulating corticosterone generation. To address the problem, we used C323G mutant SR-BI. Our early studies indicated that this mutated SR-BI loses its apoptotic activity and anti-NO activity completely (21, 22) . Our recent data also indicated that this mutant loses its cholesterol uptake activity completely (unpublished data). Therefore, the C323G mutant SR-BI is a unique tool to determine the contribution of macrophage SR-BI to sepsis. We generated the SRBIC323G transgenic mice and bred the mice with SR-BI null mice to generate SRBIC323G transgenic mice in SR-BI null background ( Figure 5, a and b) . We isolated bone marrow cells from the transgenic and non-transgenic littermates and confirmed the expression of SRBIC323G in bone marrowderived macrophages (Figure 5c ). Then, we determined the effect of SRBIC323G on inflammatory cytokine generation using bone marrow-derived macrophages. As expected, the expression of C323G mutant SR-BI in macrophages significantly suppressed the generation of TNF-α or IL-6 as compared to nontransgenic SR-BI null mice ( Figure 5, d and e) . Finally, we challenged the transgenic mice with CLP. As shown in Figure 5 , f and g, SR-BIC323G transgenic mice did not exhibit a significant difference in plasma corticosterone levels during sepsis, but were significantly more resistant to CLP-induced septic death as compared to nontransgenic SR-BI null mice.
SR-BI modulates TLR4-mediated NF-κB activation. TLR4 is a key signaling molecule that mediates inflammatory response in macrophages during sepsis (38, 39) . LPS released from Gramnegative bacteria activates TLR4 to initiate a downstream signaling cascade, leading to the activation of NF-κB, which then activates the transcription of inflammatory genes such as TNF-α, IL-6 and iNOS (39, 40) . We tested if SR-BI modulates inflammatory response via TLR4 signaling using a HEK-Blue cell system. HEKBlue cell stably expresses TLR4, CD14, MD2 and NF-κB reporter, so it is a convenient system to elucidate TLR4 signaling. We generated HEKBlue cells that stably express SR-BI or vector ( Figure 6a ). As shown in Figure 6b , LPS induced activation of NF-κB in a LPS dose-dependent manner. Importantly, the presence of SR-BI significantly suppressed LPS-stimulated NF-κB activation, indicating that SR-BI can modulate TLR4-mediated inflammatory signaling. We also generated HEK-Blue cells stably expressing SRBIC323G (Figure 6a ). Similar to wild type SR-BI, the C323G mutant SR-BI effectively suppressed TLR4-mediated NF-κB activation (Figure 6c) .
Effect of SR-BI on lipoprotein profiles during sepsis. Lipoproteins, especially HDL, have been shown to bind LPS and neutralize LPS toxicity (41,42). As an HDL receptor, SR-BI plays an important role in regulating plasma lipoprotein metabolism. Mice deficient in SR-BI have a 2-fold increase in plasma cholesterol levels and larger HDL particles as compared to wild type controls (10) . This raises a possibility that changes in lipoprotein levels in SR-BI null mice may contribute to susceptibility to sepsis. To determine the role of SR-BI in lipoprotein metabolism during sepsis, we measured serum cholesterol levels and analyzed lipoprotein profiles 20 hours after CLP treatment. CLP treatment slightly increased plasma cholesterol levels in both SR-BI null and wild type control mice, but the differences were not statistically significant: SR-BI -/-basal, 211. (27, 43) , suggesting that SR-BI might play a role in bacteria clearance in sepsis. We collected blood and quantified the Gram-negative bacteria using blood agar culture. No significant difference in bacteria number in the blood was observed between SR-BI null and wild type control mice 20 hours after CLP challenge (SRBI +/+ , 267050 ± 460503/ml blood vs. SR-BI -/-, 234972 ± 500872/ml blood. n=12, p=0.9). Kupffer cells in the liver constitute the major pool of macrophages in the body. To determine whether SR-BI affects bacteria uptake by macrophages during sepsis, we isolated total DNA from the liver and quantified bacteria with qPCR using bacteria specific primers. Wild type mice tended to have more bacteria in the liver compared to SR-BI null mice 20 hours after CLP challenge, but the difference is not statistically significant (SRBI +/+, 183333 ± 227167/g tissue vs. SR-BI -/-, 39166 ± 20836/g tissue. n=6, p=0.17).
Effect of SR-BI on LPS clearance during sepsis. SR-BI has been shown to bind LPS and enhance LPS intracellular uptake in vitro (27, 43) , which raises possibility that SR-BI might facilitate LPS clearance during sepsis. We measured plasma LPS levels in CLP-challenged mice. SR-BI null mice had a significantly higher plasma LPS levels than wild type controls 20 hours following CLP treatment, indicating that SR-BI is required for LPS clearance during sepsis (Figure 8 ). We also noticed that, compared to wild type controls, SR-BI null mice had lower plasma LPS levels in the early stage of sepsis, indicating that SR-BI is required for LPS recruitment from inflammation site to circulation (Figure 8) .
DISCUSSION
This study demonstrates that SR-BI is a critical survival factor of sepsis in mice. In contrast to significant protection by SR-BImediated corticosterone production in LPSinduced endotoxic animal death, corticosterone did not provide protection against CLP-induced septic animal death. Further studies reveal that SR-BI protects against septic death through its role in modulating inflammatory responses in macrophages and facilitating LPS recruitment and clearance.
Role of SR-BI in corticosterone generation during sepsis and its contribution to septic death. SR-BI is required for inducible corticosterone generation in stressful conditions such as endotoxemia, cold water swimming and long-term starvation (26, 44) . Cai et al. reported that supplementation of corticosterone to SR-BI null mice effectively rescued mice from LPS-induced endotoxic death (decreasing mortality from 100% to 57%), indicating that SR-BI-mediated corticosteroid production plays a major protective role in endotoxemia (26) . In this study, we determine the role of SR-BI in corticosterone generation during sepsis and its contribution to septic death. We demonstrate that SR-BI is required for inducible corticosterone production during sepsis. However, supplementation of corticosterone failed to rescue SR-BI null mice from CLP-induced animal death, which is different from the efficient protection of corticosterone against LPS-induced endotoxic death. We speculate that the paradoxical effects of corticosterone on endotoxemia and sepsis are a result of the differential immune responses involved in endotoxemia and sepsis. For endotoxemia, an injection of LPS simply induces overproduction of inflammatory cytokines, leading to tissue damage and endotoxic death. Because corticosterone has anti-inflammatory activity, it can effectively reduce LPS-induced inflammatory response and therefore prevent endotoxic animal death (26) . For sepsis, however, bacteria release LPS that stimulates the innate immune system to generate inflammatory cytokines, but the inflammatory cytokines now have both beneficial and deleterious effects. The inflammatory cytokines can potentially cause tissue damage, but they are also required for fighting against bacterial infections. If corticosterone supplementation suppresses inflammatory cytokine generation in sepsis, especially in its early stage, this would weaken the body's defense system, resulting in uncontrolled bacterial infections and ultimately septic death.
Role of SR-BI in modulating inflammatory response in macrophages and its contribution to septic death. We then looked for an alternative explanation for SR-BI's protective role in sepsis. Knowing that SR-BI is expressed in macrophage, and that macrophage is one of the major players that mediate innate immune response, we conducted three groups of experiments to test our hypothesis that SR-BI protects against septic death through its role in modulating innate immune response of macrophages. First, we determined whether expression of SR-BI in macrophages modulates inflammatory response using bone marrow-derived macrophages. Macrophages deficient in SR-BI generated significantly higher levels of TNF-α and IL-6 by 20 hours of LPS treatment as compared to wild type macrophages, indicating a prolonged and uncontrolled inflammatory response in the absence of SR-BI.
Next, we determined whether expression of SR-BI in macrophages contributes to protection against septic death. A number of approaches can be used to determine the role of SR-BI in macrophages in vivo (e.g. bone marrow transplantation has been used to determine the contribution of macrophage SR-BI to the development of atherosclerosis (23) (24) (25) ). In this study, we employed transgenic mice expressing C323G mutant SR-BI. We took advantage of several aspects of this animal model: 1) SR-BIC323G lacks cholesterol uptake activity so that we could exclude the contribution of SR-BImediated corticosteroid generation to sepsis; 2) as previously shown, SR-BI has multiple functions including induction of apoptosis and protection against NO-cytotoxicity (21,22), which may contributes to its protection against septic death. SR-BIC323G has no apoptotic or anti-NO activity so that we could also exclude these effects; 3) we can avoid the sub-lethal radiation treatment used in bone marrow transplantation that may affect the outcomes of septic study (45) . With this unique animal model, we confirmed that C323G mutated SR-BI is capable of modulating inflammatory response in macrophages, and importantly, provides protection against CLP-induced septic death.
Then, we explored whether SR-BI suppresses inflammatory response by modulating TLR4 signaling using a HEK-Blue cell system. The HEK-Blue cell stably expresses TLR4 and its cofactors CD14 and MD2. The cell also expresses a NF-κB reporter which makes it a convenient system to elucidate TLR4-mediated inflammatory signaling. We showed that LPS treatment stimulated TLR4 signaling resulting in NF-κB activation, and expression of SR-BI significantly suppressed NF-κB activation. Since TLR4 and NF-κB are upstream signaling molecules that control inflammatory cytokine production in macrophages, we conclude that SR-BI modulates the inflammatory response via TLR4 signaling.
Role of SR-BI in LPS clearance during sepsis. SR-BI enhances LPS uptake in vitro (43) . By injection of radioisotope labeled LPS, it has been shown that mice deficient in SR-BI have delayed LPS clearance from the circulation (26) . In this study, we measured plasma LPS levels to determine the effect of SR-BI on LPS metabolism during sepsis. As expected SR-BI null mice had a significantly higher plasma LPS levels than wild type controls 20 hours following CLP treatment, indicating that SR-BI is required for LPS clearance during sepsis. We also noticed an unexpected phenomenon that SR-BI null mice had lower plasma LPS levels in the early stage of sepsis compared to wild type controls, indicating that SR-BI is required for LPS recruitment from inflammation site to circulation. The defect in LPS recruitment may provide an explanation for why SR-BI null mice had delayed inflammatory responses during the early stage of sepsis.
It is worth to note that both the delay in cytokine production and subsequent enhancement in cytokine production by SR-BI null mice treated with CLP are associated with decreased survival, but this relationship is not necessarily causal. More studies are required to determine the contribution of this delayed inflammatory response to septic death.
SR-BI may contribute to protection against other inflammatory diseases (e.g. atherosclerosis) through its role in modulating inflammatory response in macrophages. Using bone marrow transplantation, early studies have shown that expression of SR-BI in macrophages protects against the development of atherosclerosis (23) (24) (25) . Interestingly, expression of SR-BI in macrophages does not alter plasma lipoprotein profiles or SR-BI-mediated cholesterol efflux in macrophages, suggesting that macrophage SR-BI exerts its protective functions via a novel mechanism, independent of its role in regulating cholesterol metabolism. While more detailed studies are required to determine the mechanisms underlying macrophage SR-BI protection against atherosclerosis, our findings that SR-BI modulates TLR4-mediated inflammatory response in macrophages provides a possible mechanism for SR-BI's protection against atherosclerosis.
In summary, we demonstrate that SR-BI is a critical protective modulator in sepsis. We reveal that SR-BI protects against septic death likely through its role in modulating immune response via TLR4 signaling in macrophages and through its role in removal of LPS from circulation. Importantly, by using a transgenic mouse model, we showed that overexpression of C323G mutant SR-BI provides protection against septic death. Our findings may provide a novel target for the intervention of sepsis. Fig. 1 . SR-BI protects against septic death in mice. a, Survival analysis. 10-to 12-week-old SR-BI null mice (solid square, n=21) and wild type littermates (solid triangle, n=19) were treated with CLP and the survival was observed for 5 days. The data were expressed as the percentage of mice survived at indicated times. p < 0.001 versus wild type. b, CLP induced liver injury. Twenty hours following CLP treatment, SR-BI null and wild type control mice (n=6 per group) were sacrificed, and the liver injury was assessed by measuring serum alanine aminotransferase (ALT) levels. Sham animals (n=6 per group) were similarly treated without ligation/puncture of the cecum. Mean ± SD. *p < 0.05 versus wild type. The construct contains enhancer-β-actin promoter-intron-SRBIC323G cDNA. b, PCR genotyping of SRBIC323G transgenic mice using P1/P2 primers. The transgenic mice were bred with SR-BI null mice to generate transgenic mice in SR-BI null background as described in the Methods. c, Expression of SRBIC323G in macrophages. Bone marrow cells from SR-BIC323G transgenic or non-transgenic littermates were cultured for 6 days. The expression of SR-BI was analyzed by Western blot (20 µg protein/lane). d and e, Effect of SR-BIC323G on TNF-α and IL-6 generation in macrophages. The macrophages were treated with LPS for 20 hours, and TNF-α and IL-6 levels were quantified (d and e, n=4 per group with triplicate measurements, mean ± SD. *p < 0.05 versus non-transgenic littermates). f and g, Effect of SR-BIC323G on survival. The SR-BIC323G transgenic and non-transgenic littermates (n=12 per group) were treated with CLP. Twenty hours later, 10 µl serum was collected from tail vein for quantifying serum corticosterone (f, n=6 per group). The survival was observed for 5 days (g). The data were expressed as the percentage of mice survived at indicated times. p = 0.01 versus non-transgenic littermates. 
